<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2023">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04652765</url>
  </required_header>
  <id_info>
    <org_study_id>COV2005</org_study_id>
    <secondary_id>IRB00254142</secondary_id>
    <nct_id>NCT04652765</nct_id>
  </id_info>
  <brief_title>Camostat With Bicalutamide for COVID-19</brief_title>
  <acronym>COMBO</acronym>
  <official_title>COMBO Trial: Camostat With Bicalutamide for COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a randomized, open-label study to determine if camostat or camostat+&#xD;
      bicalutamide decreases the proportion of people with COVID-19 who require hospitalization,&#xD;
      compared to historical controls. Patients with symptomatic COVID-19, diagnosed as&#xD;
      outpatients, will be randomized 1:1:1, stratified by gender, to treatment with standard of&#xD;
      care alone (Arm 1) or with camostat (Arm 2) or with camostat and bicalutamide (Arm 3).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants requiring hospitalization</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Number of outpatient participants diagnosed with COVID-19 who require hospitalization by day 28</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing symptoms</measure>
    <time_frame>up to 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of drug-related adverse events</measure>
    <time_frame>up to 60 days</time_frame>
    <description>Number of adverse events, as defined by NCI CTCAE version 5.0, that are related to the study drug (or therapy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of drug-related serious adverse events</measure>
    <time_frame>up to 60 days</time_frame>
    <description>Number of serious adverse events, as defined by NCI CTCAE version 5.0, that are related to the study drug (or therapy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>up to 60 days</time_frame>
    <description>Number of participants deceased.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>up to 60 days</time_frame>
    <description>Number of calendar days in the hospital</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants requiring upgrade to intermediate care unit (IMC)</measure>
    <time_frame>up to 60 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Duration of IMC stay</measure>
    <time_frame>up to 60 days</time_frame>
    <description>Number of calendar days in IMC unit</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants requiring upgrade to intensive care unit (ICU)</measure>
    <time_frame>up to 60 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Duration of ICU stay</measure>
    <time_frame>up to 60 days</time_frame>
    <description>Number of calendar days in ICU</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants requiring mechanical ventilation</measure>
    <time_frame>up to 60 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Duration on mechanical ventilation</measure>
    <time_frame>up to 60 days</time_frame>
    <description>Number of calendar days requiring mechanical ventilation</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Covid19</condition>
  <condition>SARS-CoV Infection</condition>
  <condition>Coronavirus Infection</condition>
  <arm_group>
    <arm_group_label>Standard of care (SOC)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>SARS-CoV-2 positive participants will receive SOC therapy alone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOC plus camostat</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SARS-CoV-2 positive participants will receive SOC therapy as well as camostat for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOC plus camostat and bicalutamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SARS-CoV-2 positive participants will receive SOC therapy as well as camostat and bicalutamide for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camostat Mesilate</intervention_name>
    <description>Camostat 600mg by mouth four times a day, for a total of 7 days</description>
    <arm_group_label>SOC plus camostat</arm_group_label>
    <arm_group_label>SOC plus camostat and bicalutamide</arm_group_label>
    <other_name>camostat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bicalutamide 150 mg</intervention_name>
    <description>Bicalutamide 150mg by mouth once daily, for a total of 7 days</description>
    <arm_group_label>SOC plus camostat and bicalutamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt;= 60 years of age&#xD;
&#xD;
          -  COVID-19 infection, confirmed by polymerase chain reaction (PCR) test &lt;=5 days from&#xD;
             enrollment done in the ambulatory setting&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  Symptom related to COVID-19. This includes: fever or chills, cough, shortness of&#xD;
             breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of&#xD;
             taste or smell, sore throat, congestion or runny nose, nausea or vomiting, diarrhea or&#xD;
             other symptom recognized by the Centers for Disease Control to be a symptom of&#xD;
             COVID-19.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who undergo asymptomatic screening test that is positive and remain&#xD;
             asymptomatic during the eligible time window&#xD;
&#xD;
          -  Patients who have had one or more positive more than 5 days prior to enrollment but&#xD;
             within 60 days of enrollment (ex. if a patient has a positive test 10 days prior to&#xD;
             enrollment and then a second positive test the day referred for enrollment, that&#xD;
             patient would be excluded. If a patient had a positive test 5 months ago, and then&#xD;
             another positive test the day he/she was referred for enrollment, that patient would&#xD;
             be eligible)&#xD;
&#xD;
          -  Unable to take oral medication&#xD;
&#xD;
          -  Male patients with female partners of reproductive potential who are unable to&#xD;
             maintain effective contraception during the recommended time period (during treatment&#xD;
             and for 130 days after the final dose)&#xD;
&#xD;
          -  Symptoms requiring hospitalization or immediate referral to hospital&#xD;
&#xD;
          -  Taking bicalutamide, any systemic hormonal therapy, or camostat within one month of&#xD;
             study entry&#xD;
&#xD;
          -  Known hypersensitivity to bicalutamide, or camostat, or its components.&#xD;
&#xD;
          -  On coumadin anticoagulation (because of drug-drug interaction with bicalutamide)&#xD;
&#xD;
          -  Self-reported past medical history of chronic liver disease or cirrhosis&#xD;
&#xD;
          -  Self-reported myocardial infarction within 6 months or past medical history of&#xD;
             congestive heart failure with known ejection fraction &lt; 40%&#xD;
&#xD;
          -  Taking any other investigational treatment for COVID-19 or COVID-19 prophylaxis&#xD;
             (COVID-19 vaccines and treatments allowed under FDA Emergency Use Authorization are&#xD;
             allowed.)&#xD;
&#xD;
        Women and people from all ethnic and race groups are eligible for this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine H Marshall, MD/MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Catherine H Marshall, MD/MPH</last_name>
    <phone>410-955-0231</phone>
    <email>combo-covid@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aliya Lalji, MD</last_name>
    <phone>410-502-5101</phone>
    <email>alalji1@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine H Marshall, MD/MPH</last_name>
      <phone>410-955-0231</phone>
      <email>chm@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Samuel Denmeade, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vasan Yegnasubramanian, MD/PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sabra Klein, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andy Pekosz, PhD BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 2, 2020</study_first_submitted>
  <study_first_submitted_qc>December 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2020</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Coronavirus</keyword>
  <keyword>Camostat</keyword>
  <keyword>bicalutamide</keyword>
  <keyword>TMPRSS2</keyword>
  <keyword>SARS-COV-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bicalutamide</mesh_term>
    <mesh_term>Camostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

